Skip to main content

Table 5 Insulin requirements of patients with T2DM at 3, 6, and 12 months after MSC therapy

From: Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Follow-up (months) Test for heterogeneity Analysis model Test for overall effect WMD or SMD 95% CI
I2 (%) P Z P
3 0 0.94 Fixed 3.4 0.0007 −0.89 (−1.40, −0.38)
6 0 0.56 Fixed 5.46 <0.00001 −1.22 (−1.66, −0.78)
12 0 0.53 Fixed 3.96 <0.0001 −1.07 (−1.60, −0.54)
  1. Abbreviations: T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference